News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Daniel Gerlach: Pan-KRAS inhibitors displaying potent anti-tumor activity in tumors with KRAS allele amplification
Daniel Gerlach/X
Dec 25, 2024, 15:54

Daniel Gerlach: Pan-KRAS inhibitors displaying potent anti-tumor activity in tumors with KRAS allele amplification

Daniel Gerlach, Associate Scientific Director, Computational Biology Oncology at Boehringer Ingelheim, posted on X about recent paper by him as co-author, titled “Pan-KRAS inhibitors BI-2493 and BI-2865 display potent anti-tumor activity in tumors with KRAS wild-type allele amplification” published on AACR Journals.

Authors: Antonio Tedeschi, Fiorella Schischlik, Francesca Rocchetti, Johannes Popow, Florian Ebner, Daniel Gerlach, Antonia Geyer, Valeria Santoro, Andrew S. Boghossian, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Jesse Lipp, Matthias Samwer, Michael Gmachl, Norbert Kraut, Mark Pearson, Dorothea Rudolph

Daniel Gerlach: Pan-KRAS inhibitors displaying potent anti-tumor activity in tumors with KRAS allele amplification

“Excited to share our recent work on the pan-KRAS inhibitors BI-2493 and BI-2865, displaying potent anti-tumor activity in tumors with KRAS wild-type allele amplification.

Great team effort by Boehringer Ingelheim.”

AACR Journals Andrew S. Boghossian Antonia Geyer Antonio Tedeschi BI-2493 BI-2865 Boehringer Ingelheim cancer Daniel Gerlach Dorothea Rudolph Fiorella Schischlik Florian Ebner Francesca Rocchetti Jennifer A. Roth Jesse Lipp Johannes Popow Mark Pearson Matthew G. Rees Matthias Samwer Melissa M. Ronan Michael Gmachl Norbert Kraut OncoDaily Oncology Pan-KRAS inhibitors Valeria Santoro
Special Coverage
Insight
Aug 15, 2025, 06:24
Harpreet Singh: New Era for ADCs in HER-2 + Metastatic Breast Cancer
Science
Aug 15, 2025, 06:18
Ramy Sedhom Shares Study on Inpatient Immunotherapy Outcomes
Science
Aug 15, 2025, 06:11
Miguel Bronchud: Can Use of Aprepitant During Chemotherapy Improve TNBC Outcomes?
Voices
Aug 15, 2025, 06:04
Lung Cancer in Africa: Gaps and Role of a Community of Practice - Move Against Cancer Africa
Voices
Aug 15, 2025, 05:56
Megan Burger: Huge Day for Cancer Care
Science
Aug 15, 2025, 05:47
Gerry Hanna Highlights a Study on Tumor Control and Immune Activation with Palliative Irradiation and ATR Inhibition
Blog Posts
Aug 15, 2025, 05:46
Farina Arreguin: Systematic Review on Childhood Cancer Survivorship
Voices
Aug 15, 2025, 05:30
Andrew Pannu: Pharma Oncology Focuses on Backbones and Modality-Agnostic Combinations
Voices
Aug 15, 2025, 05:21
Tata Memorial Hospital Marks July with 52 Publications on Advancing Cancer Care
Science
Aug 15, 2025, 05:13
E. John Wherry: What's the Difference Between Trm and Exhausted CD8 T cells?
Science
Aug 15, 2025, 05:00
Indraneel Deshmukh: Important data in FLT-3 TKD Mutated AML
Drugs
Aug 15, 2025, 04:34
Repotrectinib (Augtyro) Patients Guide for 2025: Targeted Therapy for ROS1 and NTRK positive Tumors